CompletedPhase 2NCT03380026
Mechlorethamine Induced Contact Dermatitis Avoidance Study
Studying Mycosis fungoides and variants
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Rochester Skin Lymphoma Medical Group, PLLC
- Principal Investigator
- Brian Poligone, MD, PhDRochester Skin Lymphoma Medical Group, PLLC
- Intervention
- Triamcinolone(drug)
- Enrollment
- 28 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2020
Study locations (1)
- Rochester Skin Lymphoma Medical Group, PLLC, Fairport, New York, United States
Collaborators
Rochester General Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03380026 on ClinicalTrials.gov